---
title: Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes
  in the EMPEROR-Preserved Trial
date: '2025-02-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39895437/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250203170930&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: Investigator adjudication is an alternative to a CEC with
  similar accuracy and faster event accumulation in HFpEF. The use of granular (SCTI)
  criteria did not improve trial performance. Our data suggest that a broader definition
  of an HHF event could be particularly beneficial in HFpEF clinical trials. (EMPagliflozin
  outcome tRial in Patients with chronic heart Failure With Preserved Ejection Fraction;
  ...'
disable_comments: true
---
CONCLUSIONS: Investigator adjudication is an alternative to a CEC with similar accuracy and faster event accumulation in HFpEF. The use of granular (SCTI) criteria did not improve trial performance. Our data suggest that a broader definition of an HHF event could be particularly beneficial in HFpEF clinical trials. (EMPagliflozin outcome tRial in Patients with chronic heart Failure With Preserved Ejection Fraction; ...